Obesity

Pharma

Lilly, Innovent's mazdutide nabs first-in-class nod in China

With a Chinese green light in obesity, Innovent and Eli Lilly's mazdutide has become the world's first commercial dual GLP-1/glucagon receptor agonist.

Fraiser Kansteiner Jun 27, 2025 11:16am

RemeGen, Harbour, Datroway—Fierce Pharma Asia

Jun 27, 2025 8:37am

Novo Nordisk questioned over Spanish obesity awareness campaign

Jun 25, 2025 10:05am

Fierce Healthcare

Hims & Hers stock drops 30% after Novo Nordisk terminates deal

Jun 23, 2025 12:00pm

Lilly fills out lineup of Zepbound doses on self-pay website

Jun 16, 2025 11:48am

PD-1 bispecifics, Enhertu, Regeneron-Hansoh—Fierce Pharma Asia

Jun 6, 2025 7:15am